Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
335
Recruiting, any sponsor type, condition "acute lymphoblastic leukemia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting335
- Completed1,125
335 trials
Showing 1 to 25, recently updated first.
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruiting
Haikou Affiliated Hospital of Central South University Xiangya School of MedicineAcademic, hospital or other
NCT07763054 · 30 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 31, 2026
Drug: Liposomal Amphotericin B · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome and 6 more
Sites: Hainan, China
National Cancer Institute (NCI)NIH
NCT07572136 · 57 participants (planned) · Start Nov 25, 2026 · Primary completion Jun 30, 2030
Drug: TSLPR-CART; Cyclophosphamide and 1 more · For: B-All; Acute Lymphoblastic Leukemia
Sites: Bethesda, Maryland
Allterum Therapeutics, IncIndustry
NCT07586618 · 24 participants (planned) · Start Jun 1, 2026 · Primary completion May 2028
Drug: 4A10 · For: Lymphoblastic Lymphoma; Acute Lymphoblastic Leukemia ALL
Sites: Aurora, Colorado; Chicago, Illinois; Indianapolis, Indiana · 9 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT04195633 · 60 participants (planned) · Start Jan 25, 2021 · Primary completion Apr 15, 2027
Drug: Cyclophosphamide; Cyclosporine and 5 more · For: Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 16 more
Sites: Seattle, Washington
Cellogen Therapeutics Pvt. Ltd.Industry
NCT07948733 · 18 participants (planned) · Start Oct 26, 2026 · Primary completion Sep 14, 2028
Drug: Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg; Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg and 1 more · For: B-Cell Non-Hodgkin Lymphoma (NHL); B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Vellore, India
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02877303 · 80 participants (planned) · Start Nov 1, 2016 · Primary completion Nov 1, 2028
Drug: Blinatumomab; Cyclophosphamide and 10 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma
Sites: Houston, Texas
National Cancer Institute (NCI)NIH
NCT04301076 · 30 participants (planned) · Start Aug 31, 2021 · Primary completion Jun 30, 2027
Drug: Cyclophosphamide; Doxorubicin Hydrochloride and 4 more · For: Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma and 1 more
Sites: Atlanta, Georgia; City of Saint Peters, Missouri; Creve Coeur, Missouri · 19 sites in all
National Cancer Institute (NCI)NIH
NCT03739814 · 84 participants (planned) · Start May 8, 2019 · Primary completion Feb 1, 2027
Drug: Blinatumomab; Inotuzumab Ozogamicin and 1 more · For: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 285 sites in all
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06317662 · 153 participants (planned) · Start Jun 5, 2025 · Primary completion Dec 31, 2028
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 17 more · For: Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 117 sites in all
Ruijin HospitalAcademic, hospital or other
NCT07301138 · 23 participants (planned) · Start Dec 15, 2025 · Primary completion Dec 31, 2028
Drug: BEBT-908; Cyclophosphamide and 4 more · For: Acute Lymphoblastic Leukemia
Sites: Shanghai, China
St. Jude Children's Research HospitalAcademic, hospital or other
NCT06289673 · 850 participants (planned) · Start Dec 26, 2024 · Primary completion May 2034
Drug: Dexamethasone; Vincristine and 4 more · For: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Mixed Phenotype Acute Leukemia
Sites: San Diego, California; Baton Rouge, Louisiana; Charlotte, North Carolina · 5 sites in all
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07854652 · 15 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 30, 2028
Drug: Ifupinostat Hydrochloride · For: B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Sites: Suzhou, China
John ReneauAcademic, hospital or other
NCT04848064 · 12 participants (planned) · Start May 6, 2022 · Primary completion Jul 30, 2027
Drug: Cyclophosphamide; Fludarabine and 2 more · For: Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Adult T-Cell Leukemia/Lymphoma and 1 more
Sites: Columbus, Ohio
Eastern Cooperative Oncology GroupResearch network
NCT05289687 · 20 participants (planned) · Start May 25, 2023 · Primary completion Jun 30, 2027
Drug: Daratumumab / Hyaluronidase Injection; Daratumumab / Hyaluronidase Injection and 2 more · For: T-cell Acute Lymphoblastic Leukemia
Sites: Chicago, Illinois
Autolus LimitedIndustry
NCT06173518 · 30 participants (planned) · Start Nov 16, 2023 · Primary completion Nov 2027
Drug: AUTO1 · For: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 15 sites in all
Incyte Biosciences International SàrlIncyte (INCY)
NCT03934372 · 70 participants (planned) · Start Jan 29, 2020 · Primary completion Feb 1, 2028
Drug: Ponatinib · For: Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia and 6 more
Sites: Ghent, Belgium; Paris, France; Poitiers, France · 23 sites in all
Sunil G. IyerAcademic, hospital or other
NCT07936266 · 45 participants (planned) · Start Mar 31, 2027 · Primary completion Dec 31, 2030
Drug: Asciminib; Inotuzumab ozogamicin · For: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Miami, Florida; Chicago, Illinois; New York, New York · 4 sites in all
City of Hope Medical CenterAcademic, hospital or other
NCT07758673 · 16 participants (planned) · Start Apr 17, 2027 · Primary completion Jul 26, 2028
Drug: Autologous BAFFR-targeting CAR T Cells; Cyclophosphamide and 1 more · For: Recurrent B Acute Lymphoblastic Leukemia; Recurrent B Lymphoblastic Lymphoma; Refractory B Acute Lymphoblastic Leukemia and 1 more
Sites: Duarte, California; Irvine, California
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1Recruiting
Ruijin HospitalAcademic, hospital or other
NCT06718244 · 20 participants (planned) · Start Oct 31, 2024 · Primary completion Dec 31, 2029
Drug: single dose of Inaticabtagene autoleucel · For: Acute Lymphoblastic Leukemia
Sites: Shanghai, China
Tanja Andrea GruberAcademic, hospital or other
NCT05848687 · 90 participants (planned) · Start Nov 3, 2023 · Primary completion Dec 2028
Drug: Dexamethasone; Mitoxantrone and 7 more · For: Lymphoblastic Leukemia
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 24 sites in all
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Pivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04546399 · 461 participants (planned) · Start Dec 17, 2020 · Primary completion Jun 30, 2028
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 9 more · For: Down Syndrome; Recurrent B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 229 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07387926 · 50 participants (planned) · Start Jul 5, 2026 · Primary completion Sep 19, 2033
Drug: Asciminib Adult formulation; Asciminib Pediatric formulation and 7 more · For: Acute Lymphoblastic Leukemia; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Sites: Sydney, Australia; Brisbane, Australia; Melbourne, Australia · 9 sites in all
- A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic LeukemiaPivotal-lookingRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07223021 · 130 participants (planned) · Start Oct 20, 2025 · Primary completion Oct 2028
Drug: Fludarabine; Cyclophosphamide and 2 more · For: B-cell Acute Lymphoblastic Leukemia
Sites: New York, New York; Cincinnati, Ohio; Philadelphia, Pennsylvania · 7 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03263572 · 90 participants (planned) · Start Nov 29, 2017 · Primary completion Nov 30, 2027
Drug: Blinatumomab; Cytarabine and 2 more · For: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression and 5 more
Sites: Houston, Texas
Liping DouAcademic, hospital or other
NCT07927816 · 12 participants (planned) · Start Sep 1, 2026 · Primary completion Aug 31, 2028
Drug: CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7) · For: Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; In Vivo CAR-T; B-Cell Acute Lymphoblastic Leukemia
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.